Cancer cells also undergo fractional killing in response to treatment with TRAIL ligand [5], and our model predicts that the incorporation of TRAIL would enhance the killing efficiency of cisplatin (Fig 3A and 3B). This evidence concerns the gene TNFSF10 and cancer.